Psychosocial Considerations in Cancer Care
Cancer treatment addresses a patient's physical health but the mental state of the patient is something that might need more than an oncologist's expertise.
Osteonecrosis of the Jaw Related to Antiresorptive Therapy
Antiresorptive medicines used to reduce the loss of bone mass related to bone metastases or treatment toxicity are associated with an increased risk of ONJ.
Oncofertility: Updates on Fertility Preservation Related to Cancer Care
Awareness and treatment of oncofertility have been given a tremendous boost over the past 5 years by the Oncofertility Consortium.
Breast Cancer Treatment Update
Beth Baughman DuPree, MD, FACS, discussed the latest in breast cancer care at the 3rd Annual NCONN Conference.
Clinical Management of Primary Brain Tumors
At NCONN 2011, Sean Grimm, MD, discussed the management of Glioblastoma multiforme, the most common malignant primary brain tumor.
3rd Annual NCONN Conference: Including insights from Harold P. Freeman, MD, FACS, the founder of patient navigation
The National Coalition of Oncology Nurse Navigators (NCONN) held its 3rd Annual Conference, Changing the Face of Cancer Care, from September 8-10 in San Diego, California.
Lynch Syndrome International
Lynch Syndrome International (LSI) fills a tremendous void in the arena of hereditary cancers by providing networking, organization, and a voice.
What is the best way to administer bendamustine, since some clinicians classify it as an irritant and others classify it as a vesicant?
Because of bendamustine's potential to cause pain and erythema to the extent that hospitalization has been required for some patients, it would be prudent to administer bendamustine using vesicant precautions.
Assessment Comes First in Navigating Young Adults With Cancer
Young adults facing a cancer diagnosis have unique needs and barriers to care and survivorship that can present a difficult challenge to ONNs.
Navigation: All Nurses Play a Role
Navigation programs in healthcare facilities are proliferating. However, there is considerable variability in their scope and implementation.
Switch Maintenance Regimens Demonstrate Similar Efficacy for Patients with RAS Wild-Type mCRC
ASH Data Offer Treatment Direction for Oncology Nursing Professionals
HRQOL Analysis Favors Tislelizumab Over Sorafenib in Hepatocellular Carcinoma
Encorafenib Triplet Elicits Antitumor Activity in BRAF V600E+ mCRC
2 Clarke Drive Cranbury, NJ 08512